2547. AUC-Guided Vancomycin Therapy for Physicians
Session: Symposium: When Does PK/PD Matter for Patient Care?
Saturday, October 6, 2018: 2:25 PM
Room: S 305-314
Michael Neely, MD, MSc, FCP, Pediatrics, Children's Hospital Los Angeles / University of Southern California, Los Angeles, CA

Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker control, simulation, and most importantly, use of models to optimize therapy for individual patients. He is a practicing pediatric infectious diseases specialist. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on anti-infective compounds, he has experience with other therapeutic areas. He is the Chief of Infectious Diseases and Director of the Laboratory of Applied Pharmacokinetics and Bioinformatics (LAPKB) at the Children's Hospital of Los Angeles and an Associate Professor of Pediatrics and Clinical Scholar at the University of Southern California (USC) Keck School of Medicine. Dr. Neely created Pmetrics, a non-parametric and parametric population modeling and simulation package for R based on over four decades of work by members of LAPKB. He also created an R package for LAPKB’s BestDose software to optimize drug therapy for individual patients. He works with multidisciplinary faculty collaborators in the USC Departments of Pediatrics, Medicine, and Preventive Medicine, as well as in the School of Pharmacy. He has a Master’s of Science in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He was a member of the United States Food and Drug Administration Anti-infective Drug Advisory Committee and now periodically consults for the committee. He is a Regent of the American College of Clinical Pharmacology, a founding member of the International Society of Pharmacometrics, and an active member of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He has been the PI on an NIH K23 training grant, two R01s, and is co-PI of a third R01, as well as co-investigator on numerous other NIH grants, with continuous NIH funding since 2007. He has published more than 100 peer-reviewed articles, mentored numerous visiting scholars, and is an invited speaker worldwide.


Disclosures:

M. Neely, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.